Enzyme Replacement Therapy Market

Global Enzyme Replacement Therapy Market Size (2023 to 2028)

The global enzyme replacement therapy market size is predicted to be valued at USD 15.53 billion by 2028 from USD 10.96 billion in 2023, growing at a CAGR of 7.22% from 2023 to 2028.

MARKET DRIVERS:

The growing prevalence of lysosomal storage disorders majorly drive the growth of the enzyme replacement therapy market. A class of uncommon genetic illnesses known as lysosomal storage disorders (LSDs) are characterised by a shortage or lack of certain enzymes essential for lysosomal function. Because of increased awareness, expanding newborn screening programmes, and improvements in diagnostic methods, LSDs are becoming more common around the globe. Enzyme replacement treatments are increasingly needed to properly control and treat these illnesses because of their expanding prevalence. The demand for ERT to treat the underlying enzyme deficits and the symptoms linked to LSDs is increasing as more individuals are given these diagnoses.

Technological advancements in the enzyme replacement therapies further fuelling the market’s growth rate. Significant developments around biotechnology have produced increasingly sophisticated and specialised enzyme replacement treatments. Recombinant enzymes may now be produced with better qualities such higher stability, specificity, and half-life thanks to advancements in recombinant DNA technology. These scientific developments have enhanced the ERT medicines' effectiveness and safety profiles, enhancing their ability to treat the underlying enzyme deficits and enhancing patient outcomes. Further investigation into gene therapy and other cutting-edge therapeutic approaches has the potential to boost ERT's efficacy in the future.

Favourable regulatory environment and designations for orphan drugs propel the market growth. Global regulatory organisations have put in place procedures to aid in the creation and endorsement of treatments for uncommon illnesses, including LSDs. Numerous ERT medications have been given the orphan drug status, which grants pharmaceutical firms benefits and regulatory assistance, including prolonged market exclusivity, tax credits, and lower regulatory costs. These incentives have spurred investment in ERT medication research and development, spurring innovation and broadening the selection of treatments that are accessible. Additionally, regulatory bodies have simplified the approval procedures for ERT medicines, facilitating quicker market entry and better patient access to these potentially life-saving therapies.

MARKET RESTRAINTS:

The high cost of these treatments is a major barrier to the market for enzyme replacement therapy (ERT). Due to the intricate manufacturing procedures required, the need for specialised infrastructure, and the relatively limited patient populations affected by uncommon genetic illnesses, ERT medications are sometimes costly. For individuals, healthcare systems, and insurance companies, this high cost may provide access difficulties. The high cost of ERT medications may make them difficult to afford and reimburse. Some patients' insurance coverage may be restricted or refused, especially in areas with underdeveloped healthcare systems or where healthcare expenditures are constrained. Patients with lysosomal storage diseases may experience delays or subpar care because of having restricted access to therapy. The cost of ERT treatments is also made more expensive by their duration.

Impact of COVID-19 on the enzyme replacement therapy market:

Enzyme Replacement Therapy (ERT) is a medical procedure used to treat people with certain genetic illnesses by replacing any enzymes that are absent or inadequate. Lysosomal storage disorders (LSDs), a class of uncommon hereditary metabolic illnesses characterised by the accumulation of chemicals inside cells because of enzyme shortages, are the main conditions that ERT is used to treat. Recombinant enzymes are given intravenously as part of ERT to supplement or swap out the deficient or absent enzyme. The enzyme is designed to specifically target and degrade the accumulating chemicals, lowering their concentrations and enhancing symptoms and disease development. Due to the rising incidence of lysosomal storage diseases, new diagnostic tools, and developments in biotechnology, the worldwide market for enzyme replacement treatment has been gradually growing.

Non-emergency medical treatments, such as diagnostic testing and the start of therapy, have sometimes been postponed or cancelled due to the pressure on healthcare infrastructure and the need to provide COVID-19 patients priority access to resources. The COVID-19 pandemic has sped up the deployment of telemedicine and remote patient monitoring technology, which is a plus to the ERT market. This has reduced interruptions in the treatment of patients getting ERT by enabling healthcare practitioners to continue supervising them remotely. Patients and healthcare professionals may now communicate in various ways thanks to virtual consultations and remote monitoring, which provide on-going assistance and direction.

REPORT COVERAGE:

This research report on the global enzyme replacement therapy market has been segmented and sub-segmented based on the type, route of administration, end-user and region.

Enzyme Replacement Therapy Market - By Enzyme:

• Imiglucerase
• Agalsidase Beta
• Taliglucerase
• Velaglucerase Alfa
• Laronidase
• Alglucosidase Alfa
• Galsulfase
• Idursulfase
• Pancreatic Enzymes
• Pegademase
• Others

Based on enzyme, the imiglucerase segment is predicted to capture the major share of the global market during the forecast period. The growing prevalence and awareness of Gaucher disease worldwide, favorable reimbursement policies and healthcare infrastructure supporting the use of imiglucerase and established efficacy and safety profile of imiglucerase in reducing symptoms and improving quality of life in Gaucher disease patients majorly drive the growth of the imiglucerase segment in the worldwide market.

The velaglucerase alfa segment is anticipated to account for a considerable share of the global market during the forecast period owing to the increased adoption of velaglucerase alfa due to its efficacy in managing Gaucher disease symptoms. The rising demand for personalized medicine and targeted therapies in rare genetic disorders and increasing number of collaborations between pharmaceutical companies and healthcare organizations to enhance patient access and affordability of velaglucerase alfa treatment further boost the growth rate of the velaglucerase alfa segment in the global market.

The agalsidase beta segment is expected to hold a substantial share of the global market during the forecast period. Increasing diagnosis of Fabry disease and awareness among healthcare professionals, rising demand for targeted therapies for rare genetic disorders like Fabry disease and ongoing research and development efforts to enhance the therapeutic efficacy and accessibility of agalsidase beta treatment propel the segmental growth.       

The Laronidase segment is another lucrative segment and is projected to account for a considerable share of the global market during the forecast period. Increasing diagnosis of MPS I and awareness among healthcare professionals, established clinical evidence demonstrating the efficacy of laronidase in improving clinical outcomes in MPS I patients and rising emphasis on early diagnosis and treatment initiation in rare genetic disorders like MPS I propel the growth of Laronidase segment.

Enzyme Replacement Therapy Market - By Route of Administration:

• Oral
• Parenteral

Based on route of administration, the parenteral segment is expected to hold the major share of the global market during the forecast period owing to the greater control of parenteral route of administration over the delivery and absorption of the enzyme ensuring a more precise and targeted therapeutic effect. The ability of parenteral administration to achieve higher systemic concentrations of the enzyme potentially leading to enhanced efficacy further boost the growth rate of the parenteral segment in the global market.

The oral segment is predicted to register a healthy CAGR during the forecast period owing to the increasing patient preference for oral administration as it is convenient and non-invasive method of drug delivery. Ease of self-administration that allow patients to take their medication at home without the need for healthcare professional assistance, growing R&D efforts to develop oral formulations of enzyme replacement therapies and the potential advantages such as improved bioavailability and stability of certain enzymes when administered orally further boost the growth rate of the oral segment in the global market.

Enzyme Replacement Therapy Market - By End-Use:

Based on end-user, the hospital segment is anticipated to account for the largest share of the global market during the forecast period owing to the availability of advanced healthcare infrastructure, specialized medical personnel, and supportive facilities for administering enzyme replacement therapy. Hospitals are equipped with diagnostic capabilities and expertise in managing complex medical conditions, making them suitable settings for enzyme replacement therapy. The growing number of collaborations between hospitals and pharmaceutical companies to ensure the availability and proper administration of enzyme replacement therapies and hospital-based clinical research and development activities further boost the growth rate of the hospital segment in the ERT market.

The infusion centers segment is predicted to witness a healthy CAGR during the forecast period owing to the growing recognition of the benefits of specialized infusion centers in delivering enzyme replacement therapy efficiently and safely. The convenience and comfort provided to patients by dedicated infusion centers that often offer personalized care and a supportive environment, growing number of collaborations between pharmaceutical companies and infusion centers to ensure the availability and proper administration of enzyme replacement therapies and rising preference for outpatient-based treatments promote the infusion centers segment in the global market.

Enzyme Replacement Therapy Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

North America held the largest share of the global market in 2022 and the domination of the North American region in the worldwide market is likely to continue throughout the forecast period. The presence of advanced healthcare infrastructure, including well-established hospitals, research centers, and pharmaceutical companies that contribute to the development and adoption of enzyme replacement therapies is one of the major factors propelling the North American market growth. The high prevalence of rare diseases and genetic disorders that create a substantial patient pool requiring enzyme replacement therapy, strong regulatory framework and reimbursement policies supporting the availability and accessibility of ERTs further boost the growth rate of the North American market. The U.S. is anticipated to account for the major share of the North American market during the forecast period. The growing R&D efforts, clinical trials and increasing number of collaborations between academic institutions, pharmaceutical companies, and healthcare organizations that promote advancements in ERTs drive the U.S. market growth.

Europe is a prominent regional market for enzyme replacement therapy and is expected to account for a substantial share of the global market during the forecast period. The presence of well-developed healthcare systems and robust infrastructure in Europe that enable efficient diagnosis, treatment, and management of rare diseases requiring enzyme replacement therapy drive the growth of the European market. The growing awareness and diagnosis of genetic disorders that lead to the identification of more patients who can benefit from ERTs and strong emphasis on research and development with numerous clinical trials and collaborations in the field of enzyme replacement therapy further fuel the growth rate of the European market. Supportive regulatory frameworks and favorable reimbursement policies promoting the availability and affordability of ERTs promote the European market growth.

APAC is the most lucrative regional markets for enzyme replacement therapies and is expected to grow at a promising CAGR during the forecast period. The presence of a large and growing population, rising prevalence of rare diseases and genetic disorders that require enzyme replacement therapy, improving healthcare infrastructure and increasing investments in the healthcare sector propel the APAC market growth. The growing healthcare expenditures, rising awareness among patients and healthcare professionals about the availability and benefits of enzyme replacement therapy and the expansion of pharmaceutical companies and clinical research organizations in the APAC region further fuel the growth rate of the APAC market.

Latin America is expected to capture a considerable share of the worldwide market during the forecast period. The rising awareness and diagnosis of rare diseases and genetic disorders, improving healthcare infrastructure and access to specialized healthcare services and increasing number of initiatives and regulatory efforts from the governments of Latin American countries to support the development and accessibility of ERTs propel the Latin American market growth.

KEY MARKET PLAYERS:

Sanofi Genzyme, Shire, Pfizer Inc., Biomarin Pharmaceutical Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics Inc., AbbVie Inc., Sobi, Genzyme Corporation and Protalix BioTherapeutics Inc. are some of the major companies in the global enzyme replacement therapy market and profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

• In June 2021, the FDA increased the indication for elosulfase alfa (Vimizim), an enzyme replacement medication for Morquio A syndrome, a lysosomal storage disease. The clearance covered 1-year-olds.
• In September 2020, Sangamo Therapeutics reported promising interim findings from a Phase 1/2 clinical study of SB-913, a gene therapy for MPS II (Hunter syndrome). MPS II patients get a long-term enzyme supply from the treatment.